Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks). Methods: The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse. Results: The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%,p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment. Interpretation: Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350 · cited 1×
“Because using an external comparator could introduce confounding, a sensitivity analysis was conducted using propensity scores to balance treatment groups,(18) and a tipping-point analysis (E-value) was used to estimate, in terms of a relative risk, the amount of unmeasured confounding that would have been required to…”
MethodInternational consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationKitley, J., Leite, M. I., Nakashima, I., Waters, P., McNeillis, B., Brown, R., Takai, Y., Takahashi, T., Misu, T., Elsone, L., et al. (2012) · Brain · doi:10.1093/brain/aws109 · Cited by 438
Self-citation
Cited by
Kümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Jarius, S., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-11910-z · Cited by 258
Self-citation
Metadata
- Authors
- Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja‐Guevara, C., Palace, J., Paul, F., Pozzilli, C., Yountz, M., Allen, K., Mashhoon, Y., & Kim, H. J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2023-04-05
- Volume
- 93
- Issue
- 6
- Pages
- 1053-1068
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W4323036933
- Cited by
- 212
- References
- 6
- FWCI
- 34.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. https://app.cochat.ai/papers/10.1002/ana.26626
- The paper
- Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja‐Guevara, C., Palace, J., Paul, F., Pozzilli, C., Yountz, M., Allen, K., Mashhoon, Y., & Kim, H. J. (2023). Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology. https://doi.org/10.1002/ana.26626
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.